|
Mayo Clinic researchers use magnetic attraction to improve stents, reduce blood clot risk
November 03, 2006ROCHESTER, Minn. - Mayo Clinic heart researchers have devised a new strategy to improve the effectiveness and safety of heart stents, which are used to open narrowed blood vessels and have been the recent subject of clotting concerns. Their novel approach is based on magnetizing healing cells from the patient's blood so the cells are quickly drawn to magnetically coated stents.
The research report appears in the Nov. 7 issue of the Journal of the American College of Cardiology ( http://content.onlinejacc.org/ ). The Mayo team describes encouraging results from preclinical testing.
In the study, the cells were extracted from blood, and tiny iron-based paramagnetic particles were placed within the cells. Each stent was implanted through a tube (catheter) threaded through the blood vessels. Researchers then introduced the iron-tagged cells back into the blood vessel to test how well the magnetized stents captured the cells.
Because the healing cells - also known as endothelial progenitor cells derived from circulating blood - naturally fight blood clot formation, their swift magnetically guided arrival to the stent may reduce the chances of blood clot formation by lining the site fully and quickly, Mayo researchers say.
Results show a sixfold to 30-fold improvement in the magnetized stents' performance in capturing the healing endothelial cells, compared to the standard stents' ability to do so.
"The ability to rapidly coat implanted devices with living cells could accelerate local tissue healing and thereby reduce the risk of blood clot formation," says cardiologist Gurpreet Sandhu, M.D., Ph.D., lead investigator. "Our approach of magnetic cell targeting is the next generation of strategies for improving the safety of stents - and it appears that magnetic forces may provide an elegant solution for cell capture. Additionally, this new magnetic targeting technology can be adapted to develop new cell-, gene- and drug-based treatments for cancer and other human diseases."
Dr. Sandhu adds that, while encouraging, the method is still experimental and not ready to be used on human patients. Researchers are refining their approach, including developing new biomaterials.
Significance of the Mayo Research
"Many people are currently concerned about the risk of blood clots associated in a small percentage of patients with the use of drug-eluting stents," says cardiologist and cardiac researcher Robert Simari, M.D., who co-authored the paper. "Our approach holds the potential to overcome the limitations of the current drug-eluting stent technology because we address the basic conditions of clot formation. One of the reasons clots can form in drug-eluting stent patients is that the area surrounding the stent is not relined fully or quickly enough with the cells in the body, called endothelial cells, that naturally fight blood clots. Our system delivers endothelial cells right where they need to be, rapidly, with the potential for limiting clot formation."
How It Works
Multiple steps led to the development of the new Mayo magnetic cell targeting stent system. For example, the researchers had to devise:
- a way to successfully get endothelial cells derived from blood and grown in lab dishes to live and proliferate when tagged with tiny amounts of magnetically responsive material known as iron-based paramagnetic microspheres.
- specially fabricated stainless steel stents coated with magnetic materials that demonstrated excellent ability to capture the magnetically tagged endothelial cells.
Mayo Clinic
Because the healing cells - also known as endothelial progenitor cells derived from circulating blood - naturally fight blood clot formation, their swift magnetically guided arrival to the stent may reduce the chances of blood clot formation by lining the site fully and quickly, Mayo researchers say.
Results show a sixfold to 30-fold improvement in the magnetized stents' performance in capturing the healing endothelial cells, compared to the standard stents' ability to do so.
"The ability to rapidly coat implanted devices with living cells could accelerate local tissue healing and thereby reduce the risk of blood clot formation," says cardiologist Gurpreet Sandhu, M.D., Ph.D., lead investigator. "Our approach of magnetic cell targeting is the next generation of strategies for improving the safety of stents - and it appears that magnetic forces may provide an elegant solution for cell capture. Additionally, this new magnetic targeting technology can be adapted to develop new cell-, gene- and drug-based treatments for cancer and other human diseases."
Dr. Sandhu adds that, while encouraging, the method is still experimental and not ready to be used on human patients. Researchers are refining their approach, including developing new biomaterials.
Significance of the Mayo Research
"Many people are currently concerned about the risk of blood clots associated in a small percentage of patients with the use of drug-eluting stents," says cardiologist and cardiac researcher Robert Simari, M.D., who co-authored the paper. "Our approach holds the potential to overcome the limitations of the current drug-eluting stent technology because we address the basic conditions of clot formation. One of the reasons clots can form in drug-eluting stent patients is that the area surrounding the stent is not relined fully or quickly enough with the cells in the body, called endothelial cells, that naturally fight blood clots. Our system delivers endothelial cells right where they need to be, rapidly, with the potential for limiting clot formation."
How It Works
Multiple steps led to the development of the new Mayo magnetic cell targeting stent system. For example, the researchers had to devise:
- a way to successfully get endothelial cells derived from blood and grown in lab dishes to live and proliferate when tagged with tiny amounts of magnetically responsive material known as iron-based paramagnetic microspheres.
- specially fabricated stainless steel stents coated with magnetic materials that demonstrated excellent ability to capture the magnetically tagged endothelial cells.
Mayo Clinic
Stents News and Current Stents Events RSSNew paradigm for cell-specific gene delivery
Researchers from Northwestern University and Texas A & M University have discovered a new way to limit gene transfer and expression to specific tissues in animals.
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
The more than ten million Americans who've received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine.
Landmark study reveals superiority of bivalirudin in heart attack patients at 30 days
The Cardiovascular Research Foundation (CRF) announced today that the New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent.
Bypass not to blame for heart patients' mental decline
Heart patients often experience lasting problems with memory, language, and other cognitive skills after bypass surgery. However, these problems aren't caused by the surgery itself or the pump used to replace heart function during surgery, a new study by Johns Hopkins researchers suggests.
MIT crafts bacteria-resistant films
Having found that whether bacteria stick to surfaces depends partly on how stiff those surfaces are, MIT engineers have created ultrathin films made of polymers that could be applied to medical devices and other surfaces to control microbe accumulation.
In blood vessel stents, innovative materials allow better control, delivery of gene therapy
Before gene therapy becomes practical for treating human diseases, researchers must master the details of safe and effective delivery.
Combining liver cancer treatments doubles survival rates, UVA researchers find
By combining the use of stents and photodynamic therapy, also called SpyGlass, physicians at the University of Virginia have been able to significantly increase survival rates for patients suffering from advanced cholangiocarcinoma, cancer of the liver bile duct.
Comparison of anticoagulants for angioplasty show similar outcomes
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents.
The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.
Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers
Researchers at Henry Ford Hospital today announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new option for those suffering with advanced emphysema.
More Stents News Articles
 | The Double Helix: A Personal Account of the Discovery of the Structure of DNA (Norton Critical Editions) by James D. Watson |
 | The Global Politics of Energy by Jeffrey Bader, Stephen Biegun, Ivo Bozon, Diana Farrell, Jay Gulledge, Robert Hefner, John Podesta, Dennis Ross, David Rothkopf, Angela Stent, David Victor, Daniel Yergin |
 | Paradoxes of Free Will (Transactions of the American Philosophical Society, V. 92, Pt. 6) (Transactions of the American Philosophical Society, V. 92, Pt. 6) by Gunther S. Stent |
| The Coming of the Golden Age. A View of the End of Progress by Gunther S. Stent | |
 | Carotid Interventions |
 | Phage And the Origins of Molecular Biology, The Centennial Edition |
 | Nazis, Women and Molecular Biology by Gunther Stent |
| Molecular Genetics; An Introductory Narrative by Gunther Siegmund Stent | |
 | Atlas of Interventional Cardiology (Atlas of Heart Diseases (Unnumbered).) (Atlas of Heart Diseases (Unnumbered).) |
 | Handbook of Coronary Stents |
| © 2008 BrightSurf.com |